HK1219753A1 - 包含包封的antagomir的组合物 - Google Patents

包含包封的antagomir的组合物 Download PDF

Info

Publication number
HK1219753A1
HK1219753A1 HK16107653.5A HK16107653A HK1219753A1 HK 1219753 A1 HK1219753 A1 HK 1219753A1 HK 16107653 A HK16107653 A HK 16107653A HK 1219753 A1 HK1219753 A1 HK 1219753A1
Authority
HK
Hong Kong
Prior art keywords
mir
sequence
seq
nucleotide
microspheres
Prior art date
Application number
HK16107653.5A
Other languages
English (en)
Chinese (zh)
Inventor
‧阿莘
M-A‧阿莘
‧費雷特
E‧费雷特
‧佩雷茲
A‧佩雷兹
‧戈塔爾達
N‧B‧戈塔尔达
‧羅德裡奎茲西諾瓦斯
A‧罗德里奎兹西诺瓦斯
‧瓦爾特
I‧B‧瓦尔特
‧加西亞-多拉多加西亞
A‧D‧加西亚-多拉多加西亚
Original Assignee
皮埃尔法伯制药股份有限公司
瓦尔德西布伦大学基金会医院-德雷塞卡研究所
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 皮埃尔法伯制药股份有限公司, 瓦尔德西布伦大学基金会医院-德雷塞卡研究所 filed Critical 皮埃尔法伯制药股份有限公司
Publication of HK1219753A1 publication Critical patent/HK1219753A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16107653.5A 2013-01-24 2014-01-23 包含包封的antagomir的组合物 HK1219753A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305082.3A EP2759595B1 (en) 2013-01-24 2013-01-24 Composition comprising an encapsulated antagomir
EP13305082.3 2013-01-24
PCT/IB2014/058500 WO2014115103A1 (en) 2013-01-24 2014-01-23 Composition comprising an encapsulated antagomir

Publications (1)

Publication Number Publication Date
HK1219753A1 true HK1219753A1 (zh) 2017-04-13

Family

ID=47683670

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16107653.5A HK1219753A1 (zh) 2013-01-24 2014-01-23 包含包封的antagomir的组合物

Country Status (16)

Country Link
US (1) US20150352055A1 (cg-RX-API-DMAC7.html)
EP (2) EP2759595B1 (cg-RX-API-DMAC7.html)
JP (1) JP2016506923A (cg-RX-API-DMAC7.html)
KR (1) KR20160018451A (cg-RX-API-DMAC7.html)
CN (1) CN105229151A (cg-RX-API-DMAC7.html)
AU (1) AU2014208419A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015017650A2 (cg-RX-API-DMAC7.html)
CA (1) CA2898958A1 (cg-RX-API-DMAC7.html)
ES (2) ES2606636T3 (cg-RX-API-DMAC7.html)
HK (1) HK1219753A1 (cg-RX-API-DMAC7.html)
HU (1) HUE032125T2 (cg-RX-API-DMAC7.html)
MX (1) MX2015009323A (cg-RX-API-DMAC7.html)
PL (1) PL2759595T3 (cg-RX-API-DMAC7.html)
RU (1) RU2668794C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014115103A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201505602B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2864482A4 (en) 2012-06-21 2016-02-10 Miragen Therapeutics Inc OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN
HK1249108A1 (zh) * 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3601565A4 (en) * 2017-03-25 2021-01-06 Miragen Therapeutics, Inc. MIR-92 INHIBITORS IN THE TREATMENT OF HEART FAILURE
EP3939575B1 (en) * 2019-03-14 2026-07-01 M. Technique Co., Ltd. PLGA MICROPARTICLES, DELAYED-RELEASE FORMULATION OF THESE AND THEIR MANUFACTURE PROCESS
CN110484537B (zh) * 2019-09-02 2021-07-27 中国水产科学研究院淡水渔业研究中心 一种miR-92促进剂及其注射剂的制备方法和应用
CN110804659B (zh) * 2019-10-23 2023-02-03 华南农业大学 一种血清外泌体ssc-miR-92b-3p作为母猪早期妊娠诊断分子标志物的应用
CN110917359A (zh) * 2019-11-21 2020-03-27 武汉理工大学 离子键自组装制备PEG-P(Asp-AP)-ANTAGOMIR-RNA微球
WO2021251526A1 (ko) * 2020-06-11 2021-12-16 주식회사 프로스테믹스 신규한 mirna 유사체 및 이의 용도
CN111729088B (zh) * 2020-08-21 2020-12-15 江苏申基生物科技有限公司 一种微小核糖核酸miR-34a偶联探针及其制备方法
WO2025050037A1 (en) * 2023-08-31 2025-03-06 The Regents Of The University Of Colorado, A Body Corporate Microrna-15b antagomir and cerium oxide nanoparticles, and uses of same for treatment of intrauterine growth restriction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7641643B2 (en) * 2003-04-15 2010-01-05 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
WO2005013901A2 (en) * 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
DK2205737T3 (da) * 2007-10-04 2013-05-21 Santaris Pharma As Mikromirer
DE102007052114B4 (de) * 2007-10-30 2011-01-05 T2Cure Gmbh Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle
GB0814302D0 (en) * 2008-08-05 2008-10-01 Coretherapix Slu Compounds and methods
KR20120047214A (ko) * 2009-05-20 2012-05-11 보드 오브 리전츠 더 유니버시티 오브 텍사스 시스템 심근경색 후 리모델링 및 심부전에 관련된 마이크로―rna의 확인

Also Published As

Publication number Publication date
KR20160018451A (ko) 2016-02-17
US20150352055A1 (en) 2015-12-10
PL2759595T3 (pl) 2017-09-29
EP2759595A1 (en) 2014-07-30
CA2898958A1 (en) 2014-07-31
JP2016506923A (ja) 2016-03-07
ES2606636T3 (es) 2017-03-24
WO2014115103A1 (en) 2014-07-31
HUE032125T2 (en) 2017-08-28
AU2014208419A1 (en) 2015-08-13
EP2948551A1 (en) 2015-12-02
CN105229151A (zh) 2016-01-06
RU2015134770A (ru) 2017-03-03
BR112015017650A2 (pt) 2017-11-21
ZA201505602B (en) 2017-05-31
ES2688160T3 (es) 2018-10-31
EP2759595B1 (en) 2016-09-14
RU2668794C2 (ru) 2018-10-02
EP2948551B1 (en) 2018-05-02
MX2015009323A (es) 2016-04-04

Similar Documents

Publication Publication Date Title
EP2948551B1 (en) Composition comprising an encapsulated antagomir
EP2552454B1 (en) ANTAGONISTS OF miRNA-29 EXPRESSION AND THEIR USE IN THE PREVENTION AND TREATMENT OF AORTIC ANEURYSMS
KR102246814B1 (ko) 치료용 올리고뉴클레오타이드
JP2013514372A (ja) 虚血および虚血−再灌流傷害におけるマイクロrna調節
CN102803284A (zh) 用于miRNA抑制剂和模拟物的化学修饰基序
JP2015525081A5 (cg-RX-API-DMAC7.html)
EP3765619B1 (en) Inhibitors of micro-rna 22
EP3816285A1 (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition, for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
EP3329004B1 (en) Therapeutic oligonucleotides
Wang et al. MicroRNA delivery based on nanoparticles of cardiovascular diseases
JPWO2015133637A1 (ja) マイクロrna封入ナノ粒子及びその医薬用途
US20260130937A1 (en) Composition and methods to reduce inflammation and promote rejuvenation
KR20190134753A (ko) 골 손실 및 근육 기능 감소와 관련된 병리학적 상태를 치료하는데 이용하기 위한 마이크로rna 19a/19b
CN120584186A (zh) 用于在静脉血栓栓塞的治疗中使用的药物组合物
BR112018001782B1 (pt) Oligonucleotídeo para uso no tratamento e/ou prevenção de uma doença que compreende o alongamento alternativo dos telômeros, oligonucleotídeo para uso no tratamento e/ou prevenção de uma condição não cancerosa associada à disfunção do telômero e composição farmacêutica
HK40051564A (en) Amphiregulin gene-specific double-stranded oligonucleotide and composition, for preventing and treating fibrosis-related diseases and respiratory diseases, comprising same
HK40045636A (en) Inhibitors of micro-rna 22
HK40045636B (en) Inhibitors of micro-rna 22